Acta Med. 2016, 59: 50-53

https://doi.org/10.14712/18059694.2016.89

Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone

Petra Bělohlávkováa, Vladimír Maisnara, Jaroslava Voglováa, Tomáš Buchlerb, Pavel Žáka

a4th Department of Internal Medicine - Hematology, Charles University, Faculty Hospital and Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic
bDepartment of Oncology, First Faculty of Medicine and Thomayer Hospital, Prague, Czech Republic

Received March 2, 2016
Accepted March 21, 2016

References

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255–1265. <https://doi.org/10.1056/NEJM200004273421706>
2. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018.
3. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113(13): 2895–2901. <https://doi.org/10.1182/blood-2008-07-170449>
4. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703–1708. <https://doi.org/10.1182/blood-2009-09-245837>
5. Rondelli D, Barosi G, Bacigalupo A, et al. Myeloproliferative Diseases Research Consortium. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115–9. <https://doi.org/10.1182/blood-2004-11-4299>
6. Kroeger N, Holler E, Kobbe G, et al. Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Results from a multicenter prospective trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007; 110: 210a.
7. Zang DY, Deeg HJ. Allogeneic hematopoietic cell transplantation for patients with myelofibrosis. Curr Opin Hematol 2009; 16(2): 140–146. <https://doi.org/10.1097/MOH.0b013e3283257ab2> <PubMed>
8. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358–367. <https://doi.org/10.1016/j.bbmt.2009.10.025> <PubMed>
9. Abelsson J, Merup M, Birgegard G, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant 2012; 47(3): 380–386. <https://doi.org/10.1038/bmt.2011.91>
10. Babushok D, Hexner E. Allogeneic transplantation for myelofibrosis: for whom, when,and what are the true benefits? Curr Opin Hematol 2014; 21(2): 114–122. <https://doi.org/10.1097/MOH.0000000000000015> <PubMed>
11. Gupta V, Malone AK, Hari PN. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2014; 20(1): 89–97. <https://doi.org/10.1016/j.bbmt.2013.10.018> <PubMed>
12. Cervantes F, Alvarez-Larran A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005; 129(6): 771–775. <https://doi.org/10.1111/j.1365-2141.2005.05524.x>
13. Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009; 83(2): 154–155. <https://doi.org/10.1111/j.1600-0609.2009.01266.x>
14. Tabarroki A, Tiu R. Immunomodulatory agents in myelofibrosis. Expert Opin Investig Drugs 2012; 21(8): 1141–54. <https://doi.org/10.1517/13543784.2012.693913>
15. Moutouh-de Parseval LA, Verhelle D, Glezer E, et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest 2008; 118(1): 248–258. <https://doi.org/10.1172/JCI32322> <PubMed>
16. Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 114(1): 78–83. <https://doi.org/10.1046/j.1365-2141.2001.02918.x>
17. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 117(2): 288–96. <https://doi.org/10.1046/j.1365-2141.2002.03443.x>
18. Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004; 22(3): 424–31. <https://doi.org/10.1200/JCO.2004.08.160>
19. Thomas DA, Giles FJ, Albitar M, Cortes JE, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006; 106(9): 1974–84. <https://doi.org/10.1002/cncr.21827>
20. Mesa RA, Steensma DP, Pardanani A, et al. A Phase 2 trial of combination low-dose thalidomide and prednisone for the treatment myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534–2541. <https://doi.org/10.1182/blood-2002-09-2928>
21. Weinkove R, Reilly JT, McMullin MF, Curtin NJ, Radia D, Harrison CN. Low-dose thalidomide in myelofibrosis. Haematologica 2008; 93(7): 1100–1. <https://doi.org/10.3324/haematol.12416>
22. Holle N, de Witte T, Mandigers C, Schaap N, Raymakers R. Thalidomide and lenalidomide in primary myelofibrosis. Neth. J Med 2010; 68(1): 293–8.
23. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013: 22; 122(8): 1395–8. <https://doi.org/10.1182/blood-2013-03-488098> <PubMed>
24. Barosi G, Bordessoule D, Briere D, et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005; 106(8): 2849–2853. <https://doi.org/10.1182/blood-2005-04-1520>
25. Thapaliya P, Tefferi A, Pardanani A, et al. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol 2011; 86(1): 96–98. <https://doi.org/10.1002/ajh.21892>
26. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108(4): 1158–64. <https://doi.org/10.1182/blood-2006-02-004572>
27. Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinica; histopahtologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009; 27(28): 4760–6. <https://doi.org/10.1200/JCO.2009.22.6548> <PubMed>
28. Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010; 25; 116(22): 4436–8. <https://doi.org/10.1182/blood-2010-05-287417> <PubMed>
29. Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol 2010; 85(2): 129–30.
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive